CMS: anti-amyloid drug Leqembi (lecanemab) would not meet the “cheap and obligatory” customary required for wider Medicare protection
CMS Sticks to Sharply Limited Coverage of New Alzheimer’s Drug, Leqembi (Managed Well beingcare Govt): For now, CMS (Notice: Centers...
.png)